XM does not provide services to residents of the United States of America.
O
O

Otis

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Otis Worldwide Corp - Issues $600 Million 5.125% Notes Due 2031

BRIEF-Otis Worldwide Corp - Issues $600 Million 5.125% Notes Due 2031 Nov 19 (Reuters) - Otis Worldwide Corp OTIS.N : OTIS WORLDWIDE CORP - ISSUES $600 MILLION 5.125% NOTES DUE 2031 Source text: [ https://tinyurl.com/2eshy93h ] Further company coverage: OTIS.N
O

Elliott's $5 billion Honeywell gambit: would a split pay off?

ANALYSIS-Elliott's $5 billion Honeywell gambit: would a split pay off? By Utkarsh Shetti and Nathan Gomes Nov 15 (Reuters) - Diversified conglomerates were long a fixture of the U.S. stock market landscape, with the Dow industrials bolstered by big names such as 3M, General Electric, United Technologies and others. But many of those companies have since broken apart, and shares of their spinoffs have surged.
U
U
C
O

Otis Worldwide Files Final Term Sheet For Offering Of €850 Million 2.875% Notes Due 2027 - SEC Filing

BRIEF-Otis Worldwide Files Final Term Sheet For Offering Of €850 Million 2.875% Notes Due 2027 - SEC Filing Nov 13 (Reuters) - Otis Worldwide Corp OTIS.N : OTIS WORLDWIDE CORP FILES FINAL TERM SHEET FOR OFFERING OF €850 MILLION 2.875% NOTES DUE 2027 - SEC FILING Source text: [ID:n0001140361-24-046514] Further company coverage: OTIS.N
O

U.S. STOCKS Zimmer Biomet, Shake Shack, Microsoft

BUZZ-U.S. STOCKS ON THE MOVE-Zimmer Biomet, Shake Shack, Microsoft Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock indexes advanced on Wednesday, with the tech-heavy Nasdaq rising to a record high, as investors assessed corporate earnings as well as crucial data showing the economy maintained a steady pace of growth in the third quarter.
A
A
B
C
C
D
E
G
M
M
N
Q
Q
V
A
K
S
U
U
G
W
Z
D
F
O

U.S. STOCKS XPO, Blueprint Medicines, AbbVie

BUZZ-U.S. STOCKS ON THE MOVE-XPO, Blueprint Medicines, AbbVie Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock indexes were muted on Wednesday as investors assessed mixed corporate results as well as crucial data showing the economy maintained a steady pace of growth in the third quarter.
A
B
C
C
D
E
M
N
Q
Q
V
A
K
S
U
U
G
W
F
O

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.